🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆
Clinical Trials in Australia / NCT01658787
Active, not recruiting Observational

Global Registry for Endovascular Aortic Treatment (GREAT)

NCT01658787 · tracked via the Priya Life Science Australia tracker
Sponsor
W.L.Gore & Associates
Phase
Observational
Started
2010-12
Last updated
2026-02-09

Condition(s) studied

Multiple Pathologies

Investigational drug(s) / intervention(s)

Endovascular aortic repair

Endovascular aortic repair: Treatment with Gore Endovascular Aortic Products.

Study summary

Prospective, observational Registry to obtain data on device performance and clinical outcomes.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Minimum age required by state regulations * Indication for aortic endovascular stent graft repair * Signed informed consent Exclusion Criteria: * N/A

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
The University of Chicago Medicine & Biological Sciences Chicago Illinois
Baylor Research Institute Plano Texas
Royal Prince Alfred Hospital Camperdown New South Wales
Coris Medicina Avançada Florianópolis Brazil
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico Milan Italy
IRCCS Policlinico San Donato Milan Italy

More W.L.Gore & Associates trials in Australia

The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study Active, not recruiting
Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis Recruiting
The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01658787 on ClinicalTrials.gov ↗ ← All trials in Australia